Celgene scores regulatory win ahead of BMS mergerCelgene has scored a major regulatory win ahead of its proposed merger with Bristol-Myers Squibb, with the FDA Share XCelgene scores regulatory win ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-scores-regulatory-win-ahead-of-bms-merger/
2nd RNA Targeted Drug Discovery SummitAt a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Share X2nd RNA Targeted Drug Discovery Summithttps://pharmaphorum.com/events/2nd-rna-targeted-drug-discovery-summit/
BMS shares fall on mixed cancer immunotherapy resultsBristol-Myers Squibb’s shares have fallen sharply in pre-opening trading after mixed results from its cancer immunotherapy Opdivo in Share XBMS shares fall on mixed cancer immunotherapy resultshttps://pharmaphorum.com/news/bms-shares-fall-on-mixed-cancer-immunotherapy-results/
BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Merck & Co notches up another lung cancer use for KeytrudaBristol-Myers Squibb’s immunotherapy Opdivo has new competition in small cell lung cancer (SCLC) after the FDA approved its Share XMerck & Co notches up another lung cancer use for Keytrudahttps://pharmaphorum.com/news/merck-co-notches-up-another-lung-cancer-use-for-keytruda/
Gilead faces lawsuit over HIV drug pricingGilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving Share XGilead faces lawsuit over HIV drug pricinghttps://pharmaphorum.com/news/gilead-faces-lawsuit-over-hiv-drug-pricing/
Celgene-BMS merger looks good to go as shareholder backs downBristol-Myers Squibb’s mega-merger with Celgene looks set to go ahead after activist hedge fund Starboard Value backed out Share XCelgene-BMS merger looks good to go as shareholder backs downhttps://pharmaphorum.com/news/celgene-bms-merger-looks-good-to-go-as-shareholder-backs-down/
Celgene gets US patent let-off ahead of BMS mergerShares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on Share XCelgene gets US patent let-off ahead of BMS mergerhttps://pharmaphorum.com/news/celgene-gets-us-patent-let-off-ahead-of-bms-merger/
Oncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerWill it happen or not? There are doubts about whether the proposed $74 billion merger of cancer drug Share XOncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerhttps://pharmaphorum.com/views-analysis-oncology/oncology-round-up-shareholders-question-bms-celgene-merger-while-merck-cos-keytruda-keeps-getting-stronger/
